



Facile synthesis of a selectively protected triazamacrocycle

Renato T. Skerlj,* Siqiao Nan, Yuanxi Zhou and Gary J. Bridger

AnorMED Inc., #200-20353 64th Ave, Langley, BC, Canada V2Y 1N5

Received 9 August 2002; revised 13 August 2002; accepted 22 August 2002

Abstract—1,7-Diaminoheptane was selectively homologated with the novel reagent *N*-(2-nitrobenzenesulfonyl)aziridine. A series of reactions then followed to afford a selectively protected 14-membered triazamacrocyclic ring. © 2002 Elsevier Science Ltd. All rights reserved.


Azamacrocycles and some of their *N*-substituted derivatives are of synthetic interest due to their unique binding properties with metal ions.¹ The addition of different pendant arms can enhance the selectivity of the azamacrocyclic ring for a metal cation, or inorganic anion depending on the cavity size and on the nature of the substituents. *N*-substituted azamacrocycles have found biomedical applications in magnetic resonance imaging^{1c} and in radioimmunotherapy.^{1d} In addition, we have shown that substituted azamacrocycles are also potent inhibitors of HIV-1 replication.^{2,3} However, methods for the regioselective *N*-functionalization of azamacrocycles are scarce.⁴ Herein, we report the synthesis of a selectively protected 14-membered triazamacrocyclic ring **7**, which allows for functionalization at any of the three nitrogen atoms and is applicable to the synthesis of larger or smaller sized azamacrocyclic rings.

Treatment of 1,7-diaminoheptane **1** (5 equiv.) with 1.0 equiv. of *N*-(2-nitrobenzenesulfonyl)aziridine⁵ in THF at room temperature resulted in a 12:1 ratio of the desired mono-alkylated product **2** (59% yield) to the corresponding bis-alkylated product (5% yield). To the best of our knowledge this is the first example of chain homologation of an amine by nucleophilic ring opening of *N*-(2-nitrobenzenesulfonyl)aziridine. Chemoselective carbamate formation at the primary amine was accomplished by the addition of *N*-*tert*-butoxycarbonyl anhydride (1 equiv.) to a solution of **2** in THF at -78°C to afford the corresponding carbamate in 63% yield after purification by flash column chromatography. Treatment of the resulting carbamate with diethylphosphoryl chloride⁶ (DEPCI) resulted in protection of the sec-

ondary amine to afford compound **3** in 67% yield, which contains three different nitrogen-protecting groups. Selective deprotection of the *N*-*tert*-butoxycarbamate protecting group was achieved by stirring a solution of **3** in CH_2Cl_2 in the presence of TFA for 40 min at room temperature, thus liberating the primary amine **4** in a yield of 85%. This material readily underwent *N*-acylation with bromoacetyl bromide in the presence of Na_2CO_3 in THF at -15°C affording the amide **5** in 89% yield. Intramolecular *N*-alkylation was accomplished by employing high dilution conditions (0.006 M) in the presence of K_2CO_3 as base in CH_3CN at 60°C resulting in isolation of the macrocycle **6** in 90% yield.⁷ With this compound in hand functionalization at any of the nitrogen atoms is possible. For instance, selective deprotection of the 2-nitrobenzenesulfonyl group was achieved using standard conditions⁸ to afford **7** in 77% yield. *N*-Alkylation of the liberated secondary amine followed by protecting group removal afforded a biological target, which was evaluated for antiviral activity.⁹ We have also shown⁷ in a related example that the DEP protecting group can be selectively removed in the presence of a 2-nitrobenzenesulfonyl group. The amide function of **7** also serves as a protecting group and we have shown⁷ that reduction to the corresponding amine in the presence of a 2-nitrobenzenesulfonamide protecting group can be achieved using $\text{BH}_3\cdot\text{THF}$. Thus, it is possible using the combination of protecting groups illustrated (Scheme 1) to selectively functionalize at any nitrogen atom of the azamacrocyclic ring.

In conclusion, we have developed a method for the synthesis of selectively protected triazamacrocycles, which allows for functionalization at any ring nitrogen atom.

* Corresponding author. E-mail: rskerlj@anormed.com

Scheme 1. ¹⁰

Acknowledgements

We thank the Analytical group at AnorMED for support.

References

- (a) Izatt, R. M.; Pawlak, K.; Bradshaw, J. S.; Bruening, R. L. *Chem. Rev.* **1995**, *95*, 2529; (b) Bianchi, A.; Micheloni, M.; Paoletti, P. *Coord. Chem. Rev.* **1991**, *110*, 17; (c) Lauffer, R. B. *Chem. Rev.* **1987**, *87*, 901; (d) Parker, D. *Chem. Soc. Rev.* **1990**, *19*, 271.
- For a review on azamacrocycles as anti-HIV agents see: *Advances in Antiviral Drug Design*; Bridger, G. J.; Skerlj, R. T.; DeClercq, E., Ed; Jai Press: Connecticut, 1999; Vol. 3, p. 161.
- (a) Bridger, G. J.; Skerlj, R. T.; Padmanabhan, S.; Martellucci, S. A.; Henson, G. W.; Struyf, S.; Witvrouw, M.; Schols, D.; De Clercq, E. *J. Med. Chem.* **1999**, *42*, 3971; (b) Bridger, G. J.; Skerlj, R. T.; Padmanabhan, S.; Martellucci, S. A.; Henson, G. W.; Abrams, M. J.; Joao, H. C.; Witvrouw, M.; De Vreese, K.; Pauwels, R.; De Clercq, E. *J. Med. Chem.* **1996**, *39*, 109; (c) Bridger, G. J.; Skerlj, R. T.; Thornton, D.; Padmanabhan, S.; Martellucci, S. A.; Henson, G. W.; Abrams, M. J.; Yamamoto, N.; De Vreese, K.; Pauwels, R.; De Clercq, E. *J. Med. Chem.* **1995**, *38*, 366.
- For a recent review on regioselective functionalization of tetraazacycloalkanes see: Denat, F.; Brandes, S.; Guillard, R. *Synlett* **1999**, *5*, 561.
- Experimental procedure for the synthesis of *N*-(2-nitrobenzenesulfonyl)aziridine: To a solution of ethanolamine (20 g, 327 mmol) and triethylamine (15 mL, 103 mmol) in anhydrous CH₂Cl₂ (280 mL) at 0°C was added 2-nitrobenzenesulfonylchloride (73 g, 327 mmol) in anhydrous CH₂Cl₂ (30 mL). The reaction mixture was stirred at room temperature for 18 h, concentrated,

diluted with ethyl acetate (1000 mL) and the organic phase washed with 1N aqueous NaOH (300 mL), saturated aqueous NaHCO₃ (300 mL), brine (300 mL) and dried over Na₂SO₄. The organic layer was concentrated to afford crude *N*-(2-hydroxyethyl)-2-nitrobenzenesulfonamide (72 g, 90%) which was carried on to the next step. ¹H NMR (300 MHz, CD₃OD) δ 3.16 (t, *J* = 5.9 Hz, 2H), 3.60 (t, *J* = 5.9 Hz, 2H), 7.79–7.88 (m, 3H), 8.09–8.12 (m, 1H); ¹³C (75 MHz, CD₃OD) δ 46.97, 62.10, 126.44, 130.84, 132.82, 135.11, 135.43, 150.00. To a solution of crude *N*-(2-hydroxyethyl)-2-nitrobenzenesulfonamide (20 g, 81.22 mmol) and triethylamine (14.2 mL, 97.46 mmol) in anhydrous CH₂Cl₂ (200 mL) at 0°C was added methanesulfonyl chloride (6.27 mL, 81.00 mmol) in anhydrous CH₂Cl₂ (20 mL). The reaction mixture was stirred at room temperature for 18 h, concentrated, diluted with ethyl acetate (1000 mL) and the organic phase was washed with saturated aqueous NaHCO₃ (200 mL), brine (200 mL) and dried over Na₂SO₄. Concentration followed by purification of the crude material by flash chromatography on silica gel using ethyl acetate/hexanes (40:60) as eluant gave the mesylate (15.8 g, 60%) as a white solid. ¹H NMR (300 MHz, CDCl₃) δ 3.03 (s, 3H), 3.51 (t, *J* = 4.5 Hz, 2H), 4.31 (t, *J* = 4.5 Hz, 2H), 5.83 (s, 1H), 7.76–7.78 (m, 2H), 7.90–7.91 (m, 1H), 8.14–8.16 (m, 1H); ¹³C (75 MHz, CD₃OD) δ 37.95, 43.26, 68.15, 126.11, 131.22, 133.51, 133.95, 134.41, 150.20. To a solution of methanesulfonic acid 2-(2-nitrobenzenesulfonylamino) ethyl ester (16.10 g, 49.3 mmol) in anhydrous benzene (350 mL) at room temperature was added KOH (16.3 g, 28.5 mmol) in H₂O (88 mL). The reaction mixture was stirred at room temperature for 1 h, concentrated, diluted with ethyl acetate (1000 mL) and the organic phase was washed with water (250 mL), brine (300 mL) and dried over Na₂SO₄. The organic layer was concentrated and the crude material was isolated as a white solid (11.7 g, 90%). ¹H NMR (300 MHz, CDCl₃) δ 2.54 (s, 4H), 7.74–7.80 (m, 3H), 8.22–8.24 (m, 1H); ¹³C (75 MHz, CDCl₃) δ 29.80, 124.77, 128.74, 131.44, 132.73, 135.32, 148.86.

6. Qian, L.; Sun, Z.; Mertes, M. P.; Mertes, K. B. *J. Org. Chem.* **1991**, *56*, 4904.
7. Skerlj, R. T.; Zhou, Y.; Wilson, T.; Bridger, G. J. *J. Org. Chem.* **2002**, *67*, 1407.
8. Fukuyama, T.; Chueng, M.; Jow, C.-K.; Hidai, Y.; Kan, T. *Tetrahedron Lett.* **1997**, *38*, 5831.
9. Skerlj, R. T.; Bridger, G. J., unpublished results.
10. Experimental procedure for the synthesis of compound **2** and characterization data for compounds **2–7**: To a stirred solution of 1,7-diaminoheptane (33.4 g, 256.30 mmol) in anhydrous THF (220 mL) at room temperature was added dropwise *N*-(2-nitrobenzenesulfonyl)aziridine (11.7 g, 51.30 mmol) in anhydrous THF (80 mL). After the addition was complete the mixture was stirred for 20 min at room temperature and concentrated in vacuo to afford crude product as a yellow oil. The oil was purified by silica gel chromatography using MeOH/NH₄OH/CH₂Cl₂ (1:1:18) as eluant to give compound **2** (10.9 g, 59% yield based on the aziridine) as a yellow oil. The bis-alkylated product (1.5 g, 5%) was also isolated as a yellow oil. Compound **2**: ¹H NMR (300 MHz, CDCl₃) δ 1.27–1.42 (m, 10H), 2.09 (br s, 4H), 2.47 (t, *J*=7.1 Hz, 2H), 2.67 (t, *J*=6.9 Hz, 2H), 2.73–2.77 (m, 2H), 3.14 (t, *J*=6.0 Hz, 2H), 7.71–7.77 (m, 2H), 7.84–7.89 (m, 1H), 8.12–8.16 (m, 1H); exact mass *m/z* calcd for C₁₅H₂₆N₄O₄S 358.1, found 359.2 [*M*+H]⁺; Compound **3**: ¹H NMR (300 MHz, CDCl₃) δ 1.24–1.25 (m, 8H), 1.28 (t, *J*=7.2 Hz, 6H), 1.41 (br s, 11H), 2.85–2.93 (m, 2H), 3.03–3.09 (m, 2H), 3.18–3.21 (m, 4H), 3.91–4.08 (m, 4H), 4.59 (br s, 1H), 6.22 (br s, 1H), 7.68–7.74 (m, 2H), 7.77–7.82 (m, 1H), 8.05–8.11 (m, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 16.48 (2C, ³*J*_{PC}=7.5 Hz), 26.97, 28.80 (3C), 29.30, 29.47, 30.33, 40.87, 42.86 (2C), 45.83 (d, ²*J*_{PC}=5.2 Hz), 47.03 (d, ²*J*_{PC}=3.6 Hz), 62.99 (2C, d, ²*J*_{PC}=5.7 Hz), 79.37, 125.54, 131.15, 132.96, 133.91, 134.01, 148.48, 156.41, exact mass *m/z* calcd for C₂₄H₄₃N₄O₉PS 594.2, found 595.3 [*M*+H]⁺; Compound **4**: ¹H NMR (300 MHz, CDCl₃) δ 1.28–1.33 (m, 12H), 1.42–1.51 (m, 4H), 2.60–2.67 (m, 5H), 2.87–2.96 (m, 2H), 3.20–3.22 (m, 4H), 4.00–4.07 (m, 4H), 7.70–7.73 (m, 2H), 7.81–7.82 (m, 1H), 8.09–8.12 (m, 1H); exact mass *m/z* calcd for C₁₉H₃₅N₄O₇SP 494.2, found 495.2 [*M*+H]⁺; Compound **5**: ¹H NMR (300 MHz, CDCl₃) δ 1.25–1.56 (m, 16H), 2.90–2.98 (m, 2H), 3.21–3.31 (m, 6H), 3.88 (s, 2H), 3.95–4.09 (m, 4H), 6.12 (br s, 1H), 6.60 (br s, 1H), 7.71–7.76 (m, 2H), 7.82–7.86 (m, 1H), 8.10–8.13 (m, 1H); exact mass *m/z* calcd for C₂₁H₃₆BrN₄O₈PS 616.1, found 617.1 [*M*+H]⁺; Compound **6**: ¹H NMR (300 MHz, CDCl₃) δ 1.25–1.70 (m, 16H), 2.90–2.99 (m, 2H), 3.19–3.47 (m, 6H), 3.93–4.04 (m, 6H), 6.30 (t, *J*=6.0 Hz, 1H), 7.65–7.69 (m, 1H), 7.72–7.77 (m, 2H), 8.16–8.19 (m, 1H); exact mass *m/z* calcd for C₂₁H₃₅N₄O₈PS 534.1, found 535.2 [*M*+H]⁺; Compound **7**: ¹H NMR (300 MHz, CDCl₃) δ 1.32 (dt, *J*=7.2, 0.6 Hz, 6H), 1.39–1.60 (m, 11H), 2.70 (t, *J*=7.4 Hz, 2H), 2.93–3.01 (m, 2H), 3.18–3.26 (m, 2H), 3.30 (s, 2H), 3.33–3.36 (m, 2H), 3.93–4.05 (m, 4H), 7.41 (br s, H), exact mass *m/z* calcd for C₁₅H₃₂N₃O₄P 349.1, found 350.2 [*M*+H]⁺.